193 related articles for article (PubMed ID: 16341742)
1. Adherence of pharmacoeconomic studies to national guidelines in the Netherlands.
Atthobari J; Bos JM; Boersma C; Brouwers JR; de Jong-van den Berg LT; Postma MJ
Pharm World Sci; 2005 Oct; 27(5):364-70. PubMed ID: 16341742
[TBL] [Abstract][Full Text] [Related]
2. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].
Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR
Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
4. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
Hoomans T; Severens JL; van der Roer N; Delwel GO
Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
[TBL] [Abstract][Full Text] [Related]
5. A comparative review of the pharmacoeconomic guidelines in South Africa.
Carapinha JL
J Med Econ; 2017 Jan; 20(1):37-44. PubMed ID: 27564849
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for performing a pharmacoeconomic analysis.
Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
[TBL] [Abstract][Full Text] [Related]
7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
8. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
Cleemput I; van Wilder P; Huybrechts M; Vrijens F
Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251
[TBL] [Abstract][Full Text] [Related]
9. Penny and pound wise: pharmacoeconomics from a governmental perspective.
van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacoeconomic studies - usability for reimbursement decisions].
Dietrich ES; Nakashima T; Ahrens S
Dtsch Med Wochenschr; 2010 Feb; 135(8):333-8. PubMed ID: 20165996
[TBL] [Abstract][Full Text] [Related]
11. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
12. Relationship between practice guidelines, formulary management, and pharmacoeconomic studies.
Schrogie JJ; Nash DB
Top Hosp Pharm Manage; 1994 Jan; 13(4):38-46. PubMed ID: 10130682
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.
Siegel JE; Torrance GW; Russell LB; Luce BR; Weinstein MC; Gold MR
Pharmacoeconomics; 1997 Feb; 11(2):159-68. PubMed ID: 10172935
[TBL] [Abstract][Full Text] [Related]
14. Principles of pharmacoeconomic analysis of drug therapy.
Freund DA; Dittus RS
Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037
[TBL] [Abstract][Full Text] [Related]
15. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
[TBL] [Abstract][Full Text] [Related]
16. Implementing pharmacoeconomic guidelines in Latin America: lessons learned.
Augustovski F; Melendez G; Lemgruber A; Drummond M
Value Health; 2011; 14(5 Suppl 1):S3-7. PubMed ID: 21839895
[No Abstract] [Full Text] [Related]
17. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation.
Wang X; Wang ZF; Xie YM; Zhang W; Liao X; Chang YP;
Chin J Integr Med; 2015 Jun; 21(6):473-80. PubMed ID: 24671571
[TBL] [Abstract][Full Text] [Related]
18. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
Anis AH; Gagnon Y
Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.
Agro KE; Bradley CA; Mittmann N; Iskedjian M; Ilersich AL; Einarson TR
Pharmacoeconomics; 1997 Jan; 11(1):75-88. PubMed ID: 10165529
[TBL] [Abstract][Full Text] [Related]
20. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
